Madrigal Pharmaceuticals, Inc. (MDGL) Revenue History
Annual and quarterly revenue from 2003 to present
MDGL Revenue Over Time (2003–2025)
MDGL Revenue Growth History
3 of 8 years with positive growth- FY2003 revenue growth
- N/A
- FY2004 revenue growth
- -86.7%
- FY2005 revenue growth
- -100.0%
- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- N/A
- FY2008 revenue growth
- +252.0%
- FY2009 revenue growth
- +5416.1%
- FY2010 revenue growth
- -89.7%
- FY2011 revenue growth
- -48.8%
- FY2012 revenue growth
- -100.0%
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- +432.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $431.3M | +50.1% |
| Q2 2026 | $364.3M | +71.2% |
| Q1 2026 | $311.3M | +126.8% |
| Q4 2025 | $321.1M | +210.8% |
| Q3 2025 | $287.3M | +362.0% |
| Q2 2025 | $212.8M | +1353.8% |
| Q1 2025 | $137.3M | — |
| Q4 2024 | $103.3M | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
MDGL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MDGL Revenue Analysis (2003–2025)
Current Revenue & Growth
As of November 8, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) generated trailing twelve-month (TTM) revenue of $1.43 billion, reflecting explosive growth of +50.1% year-over-year. The most recent quarter (Q3 2026) recorded $431.3 million in revenue, up 18.4% sequentially.
Historical Growth Trajectory
MDGL's historical revenue data shows various trends over time. Madrigal Pharmaceuticals, Inc.'s highest annual revenue of $958.4 million was recorded in 2025, an all-time high.
Revenue by Segment
MDGL's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including HIMS (+28.0% YoY) — MDGL has outperformed the peer group in revenue growth. Compare MDGL vs HIMS →
MDGL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MDGLCurrent | $1.4B | +50.1% | - | -31.3% | |
 HIMS | $2.3B | +28.0% | +73.6% | 4.5% |
MDGL Historical Revenue Data (2003–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $958.4M | +432.1% | $902.3M | 94.1% | $-300,097,000 | -31.3% |
| 2024 | $180.1M | - | $173.9M | 96.5% | $-497,875,000 | -276.4% |
| 2023 | $0 | - | $0 | - | $-380,496,000 | - |
| 2022 | $0 | - | $0 | - | $-293,571,000 | - |
| 2021 | $0 | - | $0 | - | $-242,482,000 | - |
| 2020 | $0 | - | $-471,000 | - | $-206,320,000 | - |
| 2019 | $0 | - | $-112,000 | - | $-94,972,000 | - |
| 2018 | $0 | - | $-96,000 | - | $-40,456,000 | - |
| 2017 | $0 | - | $-77,000 | - | $-31,886,000 | - |
| 2016 | $0 | - | $-156 | - | $-24,981,641 | - |
| 2015 | $0 | - | $0 | - | $-3,170,932 | - |
| 2014 | $0 | - | $-673,000 | - | $-83,951,000 | - |
| 2013 | $0 | - | $-516,000 | - | $-87,559,000 | - |
| 2012 | $0 | -100.0% | $-738,000 | - | $-61,088,000 | - |
| 2011 | $7.6M | -48.8% | $6.1M | 80.7% | $-45,432,000 | -599.1% |
MDGL Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MDGL — Frequently Asked Questions
Quick answers to the most common questions about buying MDGL stock.
Is MDGL's revenue growth accelerating or slowing?
MDGL revenue growth is accelerating. TTM revenue reached $1.4B, up +50.1% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is MDGL's revenue history from 2003 to 2026?
Madrigal Pharmaceuticals, Inc. (MDGL) revenue history spans 2003 to 2026. TTM revenue as of 2026 is $1.4B, growing at +50.1% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is MDGL's long-term revenue growth rate (CAGR)?
Madrigal Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +50.1% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for MDGL.
Why does MDGL's quarterly revenue fluctuate?
MDGL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Madrigal Pharmaceuticals, Inc.'s revenue data from 2003 to 2026 shows full historical quarterly detail on this page.
How is MDGL's revenue distributed by segment?
MDGL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does MDGL's revenue compare to industry peers?
Madrigal Pharmaceuticals, Inc. (MDGL) with TTM revenue of $1.4B and +50.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.